Clemastine

Generic Name: Clemastine

Brand Names: Wal-hist 12 Hr Relief

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆ClNO

CAS Number: 15686-51-8

Unique Ingredient Identifier: 95QN29S1ID

Background: An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

Indication: For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.

Associated Conditions: Allergic Rhinitis (AR), Angioedema, Common Cold, Urticaria

Associated Therapies: -

Clinical Trials

Clemastine in Cardiovascular Surgery

Not Applicable

Completed

Conditions: Efficacy and Safety

Interventions: Drug: Saline Solution
Drug: Clemastine

First Posted Date: 2019-02-01

Last Posted Date: 2020-01-13

Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Target Recruit Count: 100

Registration Number: NCT03826004

Locations: 🇨🇳
Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC, Beijing, Beijing, China

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

Phase 2

Recruiting

Conditions: Optic Neuritis

Interventions: Drug: Placebo
Drug: Clemastine

First Posted Date: 2015-08-13

Last Posted Date: 2024-07-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 90

Registration Number: NCT02521311

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Clemastine
Drug: Placebo

First Posted Date: 2014-01-20

Last Posted Date: 2021-10-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT02040298

Locations: 🇺🇸
UCSF Multiple Sclerosis Center, San Francisco, California, United States

Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

Phase 2

Completed

Conditions: Chronic Urticaria

Interventions: Drug: Omalizumab 75-375 mg
Drug: Placebo to omalizumab
Drug: Loratadine
Drug: Clemastine

First Posted Date: 2007-06-04

Last Posted Date: 2011-10-21

Lead Sponsor: Novartis

Target Recruit Count: 49

Registration Number: NCT00481676

Locations: 🇩🇪
Novartis Investigative Site, Munich, Germany

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy